Overview Dividends

(BNTX) BioNTech SE - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US09075V1026

Cancer Immunotherapies

Biotechnology
Market Cap in USD: 22,798m

IPO / Inception: 2019-10-10
Return 12m vs S&P 500: -29.8%

EPS (Earnings per Share)

EPS CAGR: -33.39%
EPS Trend: -79.0%

Last SUE: -0.19
Qual. Beats: 0

Revenue

Rev. CAGR: -29.16%
Rev. Trend: -59.9%

Last SUE: 1.27
Qual. Beats: 1

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	35.1%
Value at Risk 5%th	49.0%
Relative Tail Risk	-15.21%

Reward TTM
Sharpe Ratio	-0.36
Alpha	-32.06
CAGR/Max DD	-0.36

Character TTM
Hurst Exponent	0.366
Beta	0.918
Beta Downside	0.341

Drawdowns 3y
Max DD	56.44%
Mean DD	40.64%
Median DD	41.40%

Description: BNTX BioNTech SE December 17, 2025

BioNTech SE (NASDAQ:BNTX) is a German biotechnology firm founded in 2008 and headquartered in Mainz. It focuses on developing and commercializing mRNA-based immunotherapies for cancer and infectious diseases, and trades as a common stock under the ticker BNTX in the Biotechnology sub-industry.

The company’s pipeline is heavily weighted toward oncology, with dozens of candidates spanning early to late-stage trials. Notable programs include BNT111 (Phase 2 for advanced melanoma), BNT122/RO7198457 (Phase 2 adjuvant trials in high-risk muscle-invasive urothelial carcinoma, colorectal and pancreatic cancers, plus advanced melanoma), BNT311/GEN1046 (ac-asunlimab, currently in Phase 3 for solid tumors), and BNT327 (a multi-indication platform covering small-cell lung cancer, triple-negative breast cancer, neuroendocrine neoplasms, malignant mesothelioma, EGFR-mutant NSCLC, hepatocellular carcinoma, and other solid tumors across Phases 1-3). Early-stage candidates such as BNT211 (CLDN6+ solid tumors) and BNT221 (general oncology) further broaden the portfolio.

Recent financial data show Q4 2024 revenue of approximately $1.9 billion, with COVID-19 vaccine sales still accounting for roughly 30 % of total revenue despite a multi-year decline. R&D expenditure remains high at about €1.2 billion (≈45 % of revenue), reflecting the capital-intensive nature of mRNA oncology development. The broader mRNA oncology market is projected to grow at a CAGR of ~15 % through 2030, driven by increasing regulatory acceptance and expanding pipeline activity across the sector.

For a deeper quantitative assessment of BNTX’s risk-adjusted upside, the ValueRay platform offers a concise, data-driven dashboard worth checking out.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-571.6m TTM) > 0 and > 6% of Revenue (6% = 189.2m TTM)

FCFTA -0.03 (>2.0%) and ΔFCFTA -9.24pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 431.7% (prev 525.1%; Δ -93.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.02 (>3.0%) and CFO -336.1m > Net Income -571.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (239.2m) change vs 12m ago -2.21% (target <= -2.0% for YES)

Gross Margin 82.49% (prev 84.31%; Δ -1.82pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 14.41% (prev 13.57%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -28.11 (EBITDA TTM -103.3m / Interest Expense TTM 17.3m) >= 6 (WARN >= 3)

Altman Z'' 13.60

(A) 0.64 = (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b

(B) 0.86 = Retained Earnings (Balance) 18.27b / Total Assets 21.34b

warn (B) unusual magnitude: 0.86 — check mapping/units

(D) 6.45 = Book Value of Equity 18.49b / Total Liabilities 2.86b

Total Rating: 13.60 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 12.86

1. Piotroski 1.0pt

2. FCF Yield -10.99%

3. FCF Margin -17.85%

4. Debt/Equity 0.01

5. Debt/Ebitda 95.33

6. ROIC - WACC (= -19.88)%

7. RoE -3.04%

8. Rev. Trend -59.93%

9. EPS Trend -78.98%

What is the price of BNTX shares?

As of December 19, 2025, the stock is trading at USD 91.46 with a total of 1,403,642 shares traded.
Over the past week, the price has changed by -4.73%, over one month by -10.80%, over three months by -5.04% and over the past year by -18.05%.

Is BNTX a buy, sell or hold?

BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.

Strong Buy: 13
Buy: 3
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the BNTX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	138.6	51.5%
Analysts Target Price	138.6	51.5%
ValueRay Target Price	80.5	-12%

BNTX Fundamental Data Overview December 16, 2025

Market Cap EUR = 19.40b (22.80b USD * 0.851 USD.EUR)
P/E Forward = 7.0373
P/S = 7.2316
P/B = 1.0545
P/EG = 0.0449
Beta = 1.309
Revenue TTM = 3.15b EUR
EBIT TTM = -486.7m EUR
EBITDA TTM = -103.3m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortTermDebt, last quarter)
Debt = 245.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -9.85b EUR (from netDebt column, last quarter)
Enterprise Value = 5.12b EUR (19.40b + Debt 245.4m - CCE 14.53b)
Interest Coverage Ratio = -28.11 (Ebit TTM -486.7m / Interest Expense TTM 17.3m)
FCF Yield = -10.99% (FCF TTM -562.7m / Enterprise Value 5.12b)
FCF Margin = -17.85% (FCF TTM -562.7m / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 82.49% ((Revenue TTM 3.15b - Cost of Revenue TTM 552.0m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.24 (Enterprise Value 5.12b / Total Assets 21.34b)
Interest Expense / Debt = 0.16% (Interest Expense 399.1k / Debt 245.4m)
Taxrate = 216.2% (out of range, set to none) (53.4m / 24.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = 95.33 (negative EBITDA) (Net Debt -9.85b / EBITDA -103.3m)
Debt / FCF = 17.50 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -562.7m)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.68% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -2.56% (EBIT -486.7m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -10.60% (negative operating profit) (EBIT -486.7m / (Assets 21.34b - Curr.Liab 2.22b - Cash 14.53b))
WACC = 9.28% (E(19.40b)/V(19.65b) * Re(9.40%) + (debt cost/tax rate unavailable))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
Fair Price DCF = unknown (Cash Flow -562.7m)
EPS Correlation: -78.98 | EPS CAGR: -33.39% | SUE: -0.19 | # QB: 0
Revenue Correlation: -59.93 | Revenue CAGR: -29.16% | SUE: 1.27 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-2.03 | Chg30d=+0.158 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.35 | Chg30d=+0.734 | Revisions Net=+6 | Growth EPS=+31.1% | Growth Revenue=-3.5%

Additional Sources for BNTX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle